Involvement of Norepinephrine in the Control of Activity and Attentive Processes in Animal Models of Attention Deficit Hyperactivity Disorder
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Functional and morphological studies in children affected by Attention Deficit Hyperactivity Disorder (ADHD) suggest a prefrontal cortex (PFc) dysfunction. This cortical region is regulated by subcortical systems including noradrenergic (NEergic), dopaminergic (DAergic), cholinergic, serotonergic, and histaminergic pathways. A wealth of data in humans and in animal models demonstrates altered dopamine (DA) regulation. Drugs that modulate norepinephrine (NE) transmission are also effective in ADHD patients, thus leading to the hypothesis of a NEergic disorder. This review covers the regulation of PFc functions by NE and the interaction between the NE and DA systems, as suggested by pharmacological, electrophysiological, morphological, and gene knock out (KO) studies. A negative feedback between NE and DA neurons emerges from KO studies because KO mice showing increased (NE transporter (NET) KO) or decreased (DBH and VMAT2 KO) NE levels are respectively associated with lower and higher DA levels. Locomotor activity can be generally predicted by the DA level, whereas sensitivity to amphetamines is by NE/DA balance. Some animal models of ADHD, such as spontaneously hypertensive rats (SHR), show alterations in the PFc and in the DA system. Evidence about a correlation between the NE system and hyper‐locomotion activity in such animals has not yet been clarified. Therefore, this review also includes recent evidence on the behavioral effects of two NET blockers, reboxetine and atomoxetine, in two animal models of ADHD: SHR and Naples High Excitability rats. As these drugs modulate the DA level in the PFc, certain effects are likely to be due to a rebalanced DA system. We discuss the significance of the results for theories of ADHD and make suggestions for future experimentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Aston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960
Nucleus locus ceruleus: new evidence of anatomical and physiological specificity
Foote, S. L., Bloom, F. E., & Aston-Jones, G. (1983) · Physiological Reviews · doi:10.1152/physrev.1983.63.3.844 · Cited by 1,901
Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes
Castellanos, F. X., & Tannock, R. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn896 · Cited by 1,827
Swanson, L. W. (1982) · Brain Research Bulletin · doi:10.1016/0361-9230(82)90145-9 · Cited by 1,718
Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder
Castellanos, F. X. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830070053009 · Cited by 1,183
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic
Zhou, Q.-Y., & Palmiter, R. D. (1995) · Cell · doi:10.1016/0092-8674(95)90145-0 · Cited by 731
Functional frontalisation with age: mapping neurodevelopmental trajectories with fMRI
Rubia, K., Overmeyer, S., Taylor, E., Brammer, M., Williams, S. C. R., Simmons, A., Andrew, C., & Bullmore, E. T. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00055-x · Cited by 545
Chudasama, Y., Passetti, F., Rhodes, S. E. V., Lopian, D., Desai, A., & Robbins, T. W. (2003) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.020 · Cited by 518
Cited by
Brain dopamine transporter levels in treatment and drug naive adults with ADHD
Volkow, N. D., Wang, G.-J., Newcorn, J., Fowler, J. S., Telang, F., Solanto, M. V., Logan, J., Wong, C., Ma, Y., Swanson, J. M., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.10.014 · Cited by 249
“, cingulostriatal circuits) (Kunishio and Haber, 1994), and/or other neurotransmitter systems that modulate DA activity (norepinephrine) (Viggiano et al., 2004).”
BackgroundNewman, L. A., Darling, J., & McGaughy, J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1097-8 · Cited by 137
“Imbalances in catecholamine systems are hypothesized to underlie cognitive deficits in attention deficit disorder (ADD) while many studies support a role for dopaminergic dysfunction (Barkley 1997; Sagvolden and Sergeant 1998; Castellanos and Tannock 2002; Viggiano et al. 2004b), and recent data suggest that dysfuncti…”
InfluentialEaston, N., Steward, C., Marshall, F., Fone, K., & Marsden, C. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.035 · Cited by 101
Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters
Bermingham, D. P., & Blakely, R. D. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012260 · Cited by 97
Gau, S. S.-F., & Shang, C.-Y. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990836 · Cited by 91
“While many studies support dopaminergic dysfunction underlying cognitive deficits in ADHD (Castellanos & Tannock, 2002), converging lines of data suggest that norepinephrine dysfunction may also contribute to cognitive impairments in ADHD (Newman et al. 2008 ; Viggiano et al. 2004).”
BackgroundViloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs · doi:10.1007/s40263-021-00825-w · Cited by 55
Ulke, C., Rullmann, M., Huang, J., Luthardt, J., Becker, G.-A., Patt, M., Meyer, P. M., Tiepolt, S., Hesse, S., Sabri, O., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0619-y · Cited by 43
Metadata
- Authors
- Viggiano, D., Ruocco, L. A., Arcieri, S., & Sadile, A. G.
- Venue
- Neural Plasticity
- Publisher
- Wiley
- Published
- 2004-01
- Volume
- 11
- Issue
- 1-2
- Pages
- 133-149
- ISSN
- 1687-5443 (ISSN-L)
- 2090-5904
- OpenAlex
- W2137828336
- Cited by
- 71
- References
- 19
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.